

Development of first-in-class small molecule inhibitor targeting novel transcriptional regulator for cancer immunotherapy

SAMJIN PHARM.CO.,LTD.

Disease Area	Oncology
Product Type	Small molecules
Indication	ICI-resistant solid tumor(melanoma, colon cancer and ovarian cancer)
Target	Novel transcriptional regulator function in both cancer and immune cells
Mechanism of Action	By simultaneously targeting T cells and cancer cells, SJN309 increases T cell activity and pro-inflammatory cytokines and inhibits cancer growth and immune evasion.
Competitiveness	A first-in-class small molecule inhibitor targeting novel transcriptional regulator for ICI-resistant cancer treatment
Development Stage	Hit to Lead
Route of Administration	PO
Key Data	The synergistic anti-cancer effect of SJN309 in combination with ICIs was proven in mouse syngeneic melanoma model(TGI 70%). In addition, SJN309 exhibited excellent ADME and PK profiles.
IP	Domestic application in progress